Malcolm G. Robinson

Learn More
BACKGROUND In numerous clinical trials, proton pump inhibitors have demonstrated potent acid suppression and healing of erosive oesophagitis, as well as successful symptom relief for the entire spectrum of gastro-oesophageal reflux disease. AIM The 'Future of Acid Suppression Therapy' (FAST) trial evaluated, in actual clinical practice, the timing of(More)
Proton pump inhibitors (PPIs) [omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole] are widely utilised for the treatment of gastro-oesophageal reflux disease, as well as other acid-related disorders. All PPIs suppress gastric acid secretion by blocking the gastric acid pump, H(+)/K(+)-adenosine triphosphatase (ATPase), but the(More)
The effect of low grade chronic Fasciola hepatica infection on the concentration of plasma glutamate dehydrogenase (GD), gamma-glutamyl transpeptidase (gamma-GT) and aspartate aminotransferase (AST) was investigated in sheep dosed daily with three (AL3), eight (AL8) or 14 (AL14) metacercariae over 22 weeks or given a single dose of 200 metacercariae.(More)
BACKGROUND Mesalamine is released from sulfasalazine in the colon and benefits colonic Crohn's disease. The mesalamine used in this study releases the drug throughout the small bowel and colon. Therefore, this study was designed to detect benefit for Crohn's disease involving the small bowel alone or both the colon and small bowel. METHODS This(More)
  • M Robinson
  • The Annals of otology, rhinology, and laryngology
  • 1983
An in-depth study of 610 patients who developed clinical otosclerosis before the age of 18 is reported; this is 15.1% of the total number of stapedectomy cases performed within the period 1961 to 1981. The study illustrates differences noted in those patients who had surgery performed before age 18 and those whose surgery was performed after age 18. These(More)
Two hundred thirty patients with reflux symptoms and endoscopically proven erosive esophagitis were enrolled from 15 U.S. centers into a randomized, double-blind, dose-ranging study comparing placebo with omeprazole, 20 or 40 mg given once daily in the morning. Esophagitis grade 2 was present in 44% of patients, grade 3 in 37% of patients, and grade 4 in(More)
  • M Robinson
  • International journal of clinical practice
  • 2005
Gastric acid is pathogenic in many gastrointestinal disorders, such as gastroesophageal reflux disease and peptic ulcer disease. Proton pump inhibitors (PPIs) are the antisecretory drugs of choice for serious acid-related conditions. Ample recent data exist to explicate virtually every aspect of the clinical management of acid-peptic disorders with PPIs.(More)
Recent studies have shown that impaired esophageal clearance of refluxed material during the sleeping interval plays a major role in the pathogenesis of esophagitis. The present investigation compares esophageal responses to both acid and water infusions during sleep in asymptomatic subjects. Fourteen healthy individuals were studied. The subjects were(More)
Impaired esophageal clearing of refluxed gastric contents during sleep has been implicated in the pathogenesis of reflux esophagitis. To more directly evaluate this hypothesis, 13 symptomatic patients with esophagitis and 13 normal controls had 15 ml of 0.1 N HCl instilled into the esophagus in the recumbent position while awake and during polygraphically(More)
  • M Robinson
  • Alimentary pharmacology & therapeutics
  • 2004
During the past two decades, enormous changes occurred in the management of gastric acid-related diseases. First, the histamine2-receptor antagonists were introduced, offering patients the first single-agent therapy that effectively reduced gastric acid secretion. Proton pump inhibitors became widely available in the early 1990s, and they generally appeared(More)